Overview

A Study of IMB-101 in Healthy Volunteers and Participants With Rheumatoid Arthritis

Status:
Not yet recruiting
Trial end date:
2025-12-11
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of IMB-101 in healthy volunteers and participants with active RA on a stable regimen of methotrexate.
Phase:
Phase 1
Details
Lead Sponsor:
IMBiologics Corp.